替格瑞洛增加乳腺癌耐药蛋白底物瑞舒伐他汀的暴露
本研究在9名健康志愿者中开展随机交叉试验,发现替格瑞洛使瑞舒伐他汀AUC和峰浓度均增加2.6倍,半衰期从3.1小时延长至6.6小时,肾清除率降低11%。机制可能主要与抑制肠道BCRP有关,提示应避免替格瑞洛与大剂量瑞舒伐他汀联用。
要点
- 替格瑞洛使瑞舒伐他汀AUC和Cmax均增加2.6倍,半衰期延长。
- 替格瑞洛使瑞舒伐他汀肾清除率降低11%。
- 应避免替格瑞洛与大剂量瑞舒伐他汀联用。
核心结论
- 替格瑞洛使瑞舒伐他汀血药浓度增加超过两倍,可能主要因抑制肠道BCRP所致。
- 瑞舒伐他汀所致肌毒性风险随其血浆浓度升高而增加,应避免替格瑞洛与大剂量瑞舒伐他汀联用。
研究设计与样本
- 随机交叉研究,纳入9名健康志愿者。
- 志愿者单次口服替格瑞洛90 mg或安慰剂,1小时后单次口服瑞舒伐他汀10 mg,并在首剂后12、24、36小时追加给予替格瑞洛或安慰剂。
主要发现
- 替格瑞洛使瑞舒伐他汀AUC增加2.6倍(90%CI 1.8-3.8,P=0.001),Cmax增加2.6倍(90%CI 1.7-4.0,P=0.003)。
- 替格瑞洛使瑞舒伐他汀半衰期从3.1小时延长至6.6小时(P=0.009)。
- 替格瑞洛使瑞舒伐他汀肾清除率降低11%(3%-19%,P=0.032)。
- N-去甲基瑞舒伐他汀与瑞舒伐他汀的AUC0-10h比值未受替格瑞洛影响。
- 替格瑞洛对內源性OATP1B底物(甘氨脱氧胆酸3-O-葡萄糖醛酸苷等)和NTCP底物牛磺胆酸的血浆浓度无影响。
临床怎么用
- 临床应避免替格瑞洛与大剂量瑞舒伐他汀联用,以降低肌毒性风险。
局限性
- 研究仅纳入9名健康志愿者,样本量小。
- 单次给药设计,未评估长期联用的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ticagrelor and rosuvastatin are often used concomitantly after atherothrombotic events. Several cases of rhabdomyolysis during concomitant ticagrelor and rosuvastatin have been reported, suggesting a drug-drug interaction. We showed recently that ticagrelor inhibits breast cancer resistance protein (BCRP) and organic anion transporting polypeptide (OATP) 1B1, 1B3, and 2B1-mediated rosuvastatin transport in vitro. The aim of this study was to investigate the effects of ticagrelor on rosuvastatin pharmacokinetics in humans. In a randomized, crossover study, 9 healthy volunteers ingested a single dose of 90 mg ticagrelor or placebo, followed by a single 10 mg dose of rosuvastatin 1 hour later. Ticagrelor 90 mg or placebo were additionally administered 12, 24, and 36 hours after their first dose. Ticagrelor increased rosuvastatin area under the plasma concentration-time curve (AUC) and peak plasma concentration 2.6-fold (90% confidence intervals: 1.8-3.8 and 1.7-4.0, P = 0.001 and P = 0.003), and prolonged its half-life from 3.1 to 6.6 hours (P = 0.009). Ticagrelor also decreased the renal clearance of rosuvastatin by 11% (3%-19%, P = 0.032). The N-desmethylrosuvastatin:rosuvastatin AUC0-10h ratio remained unaffected by ticagrelor. Ticagrelor had no effect on the plasma concentrations of the endogenous OATP1B substrates glycodeoxycholate 3-O-glucuronide, glycochenodeoxycholate 3-O-glucuronide, glycodeoxycholate 3-O-sulfate, and glycochenodeoxycholate 3-O-sulfate, or the sodium-taurocholate cotransporting polypeptide substrate taurocholic acid. These data indicate that ticagrelor increases rosuvastatin concentrations more than twofold in humans, probably mainly by inhibiting intestinal BCRP. Because the risk for rosuvastatin-induced myotoxicity increases along with rosuvastatin plasma concentrations, using ticagrelor concomitantly with high doses of rosuvastatin should be avoided.
引用
- Lehtisalo M, Tarkiainen EK, Neuvonen M, et al. Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin. Clin Pharmacol Ther. 2023. PMID: 37786998. doi:10.1002/cpt.3067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。